M.S. Brose

613MO A phase I clinical trial evaluating exarafenib, a selective pan-RAF inhibitor in combination with binimetinib in NRAS-mutant (NRASMut) melanoma (Mel) & BRAF-altered solid tumors

Philippe A. Cassier, Janice M. Mehnert, Richard D. Kim, B. Chmielowski et autres

fr, us, au, es (code pays fourni par la source)

604P Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status

M.S. Brose, Bhumsuk Keam, B. Robinson, Steven I. Sherman et autres

us, kr, au, pl, tw, br, hu, th, es (code pays fourni par la source)

1653P Cabozantinib (C) vs placebo (P) in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who progressed after prior VEGFR-targeted therapy: Outcomes by duration of prior lenvatinib (L) treatment

M.S. Brose, J.A. Krajewska, F. Vaisman, A.O. Hoff et autres

us, pl, br, hu, es (code pays fourni par la source)

Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer (DTC): The phase III DECISION trial

A. Bockisch, M.S. Brose, C. Nutting, Barbara Jarząb et autres

Introduction: Sorafenib (SO), an orally active inhibitor of VEGFR1 – 3 and Raf kinases, has shown promising clinical activity in single-arm phase II studies in radioactive iodine (RAI)-refractory DTC. The double-blind, randomized, multicenter phase III DECISION trial examined SO efficacy and safety …

de, us, gb, pl, it, dk, fr, kr, nl (code pays fourni par la source)

Association between tumor BRAF and RAS mutation status and clinical outcomes in patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) randomized to sorafenib or placebo: sub-analysis of the phase III DECISION trial

R Paschke, M.S. Brose, C. Nutting, Young Kee Shong et autres

Background: We recently reported that treatment of RAI-refractory DTC patients with sorafenib reduced the risk of progression or death by 42% compared to placebo in the randomized, phase III trial DECISION. We now examined BRAF and RAS mutations as possible prognostic biomarkers …

de, us, gb, kr, nl, fr (code pays fourni par la source)